ATE523488T1 - Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung - Google Patents
Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendungInfo
- Publication number
- ATE523488T1 ATE523488T1 AT06774260T AT06774260T ATE523488T1 AT E523488 T1 ATE523488 T1 AT E523488T1 AT 06774260 T AT06774260 T AT 06774260T AT 06774260 T AT06774260 T AT 06774260T AT E523488 T1 ATE523488 T1 AT E523488T1
- Authority
- AT
- Austria
- Prior art keywords
- histamine
- preparation
- therapeutic use
- compounds
- receptor agents
- Prior art date
Links
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69625705P | 2005-07-01 | 2005-07-01 | |
| PCT/US2006/025328 WO2007005503A1 (en) | 2005-07-01 | 2006-06-28 | Histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE523488T1 true ATE523488T1 (de) | 2011-09-15 |
Family
ID=37131500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06774260T ATE523488T1 (de) | 2005-07-01 | 2006-06-28 | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8008296B2 (de) |
| EP (2) | EP1904442B1 (de) |
| JP (1) | JP5193033B2 (de) |
| CN (1) | CN101263112B (de) |
| AT (1) | ATE523488T1 (de) |
| AU (1) | AU2006265997B2 (de) |
| BR (1) | BRPI0613495A2 (de) |
| CA (1) | CA2613192C (de) |
| ES (1) | ES2370518T3 (de) |
| MX (1) | MX2007016216A (de) |
| WO (1) | WO2007005503A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| DK2212282T3 (da) * | 2007-10-17 | 2012-01-23 | Sanofi Sa | Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf |
| KR20100092443A (ko) * | 2007-10-17 | 2010-08-20 | 사노피-아벤티스 | 치환된 ｎ-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 ｈ3 수용체 조절제로서의 이의 치료적 용도 |
| BRPI0818581A2 (pt) | 2007-10-17 | 2015-07-21 | Sanofi Aventis | Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas |
| PL2215058T3 (pl) * | 2007-10-17 | 2012-04-30 | Sanofi Sa | Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne |
| AR074467A1 (es) * | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras. |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1004346C2 (nl) | 1996-10-23 | 1998-04-24 | Dsm Nv | Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel. |
| WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| CA2473468C (en) * | 2002-02-01 | 2011-06-21 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| WO2004037257A1 (en) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| JP2006514614A (ja) | 2002-10-24 | 2006-05-11 | ステリックス リミテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型および２型のインヒビター |
| ATE454372T1 (de) * | 2004-04-01 | 2010-01-15 | Lilly Co Eli | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen |
| JP4572566B2 (ja) * | 2004-04-09 | 2010-11-04 | マックス株式会社 | 自走式ステープラ |
| US20060014733A1 (en) * | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
-
2006
- 2006-06-28 AT AT06774260T patent/ATE523488T1/de not_active IP Right Cessation
- 2006-06-28 CA CA2613192A patent/CA2613192C/en not_active Expired - Fee Related
- 2006-06-28 ES ES06774260T patent/ES2370518T3/es active Active
- 2006-06-28 JP JP2008519550A patent/JP5193033B2/ja not_active Expired - Fee Related
- 2006-06-28 CN CN2006800239868A patent/CN101263112B/zh not_active Expired - Fee Related
- 2006-06-28 MX MX2007016216A patent/MX2007016216A/es active IP Right Grant
- 2006-06-28 AU AU2006265997A patent/AU2006265997B2/en not_active Ceased
- 2006-06-28 US US11/917,941 patent/US8008296B2/en not_active Expired - Fee Related
- 2006-06-28 EP EP06774260A patent/EP1904442B1/de not_active Not-in-force
- 2006-06-28 EP EP11151531A patent/EP2322506A1/de not_active Withdrawn
- 2006-06-28 BR BRPI0613495-5A patent/BRPI0613495A2/pt not_active IP Right Cessation
- 2006-06-28 WO PCT/US2006/025328 patent/WO2007005503A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2613192A1 (en) | 2007-01-11 |
| MX2007016216A (es) | 2008-03-11 |
| BRPI0613495A2 (pt) | 2011-01-11 |
| JP2009500335A (ja) | 2009-01-08 |
| US8008296B2 (en) | 2011-08-30 |
| CN101263112A (zh) | 2008-09-10 |
| ES2370518T3 (es) | 2011-12-19 |
| AU2006265997B2 (en) | 2011-11-17 |
| CN101263112B (zh) | 2012-10-10 |
| CA2613192C (en) | 2013-12-31 |
| AU2006265997A1 (en) | 2007-01-11 |
| JP5193033B2 (ja) | 2013-05-08 |
| WO2007005503A1 (en) | 2007-01-11 |
| US20100160319A1 (en) | 2010-06-24 |
| EP1904442B1 (de) | 2011-09-07 |
| EP1904442A1 (de) | 2008-04-02 |
| EP2322506A1 (de) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| DE602005018758D1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| NO20074567L (no) | Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| CY1110453T1 (el) | Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |